Recent Advances in HER2+ Breast Cancer | Supplements and Featured Publications

January 16, 2020

Chau Dang, MD, discusses the evaluation of the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer in the DESTINY-Breast01 trial.

January 16, 2020

Sara A. Hurvitz, MD, discusses treatment options for patients with HER2-positive metastatic breast cancer.

January 14, 2020

Lowell L. Hart, MD, FACP, discusses detection and treatment of interstitial lung disease for patients with HER2-positive breast cancer who received fam-trastuzumab deruxtecan-nxki.

January 14, 2020

Hope S. Rugo, MD, discusses the impact of margetuximab in patients with HER2-positive metastatic breast cancer who have an F allele versus V allele.

January 13, 2020

Chau Dang, MD, discusses the APHINITY trial, which explored the use of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) plus chemotherapy in patients with HER2-positive breast cancer.

January 09, 2020

Lowell L. Hart, MD, discusses personalized treatment approaches for patients with HER2-positive breast cancer.

January 08, 2020

Madelaine Kuiper, MSN, RN, discusses the adverse event of interstitial lung disease, which can occur in patients with HER2-positive metastatic breast cancer who have received fam-trastuzumab deruxtecan-nxki.

January 08, 2020

Sarah A. Hurvitz, MD, medical oncologist, medical director, Clinical Research Unit for University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the findings in the DESTINY-Breast01 trial of patients with HER2-positive metastatic breast cancer.